Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-03

Study Completion Date

2025-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the effect of the microorganisms in the gut on how well the flu or COVID-19 vaccine works in people who have a weakened immune system due to inflammatory bowel disease. Participants can expect to be in the study for up to 65 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease

NCT04818892

IBD Covid19 Vaccine

COMPLETED

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555

Inflammatory Bowel Diseases

UNKNOWN

Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

NCT02461758

Inflammatory Bowel Disease (IBD)

COMPLETED PHASE4

Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis

NCT05333471

Chronic Granulomatous Disease-associated Colitis

RECRUITING PHASE1/PHASE2

The Role of Gut Bacteria in the Immune Response to Vaccination in Patients With Ulcerative Colitis

NCT06504784

Ulcerative Colitis

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall objective of this study is to evaluate the role of gut microbiome in influenza or COVID-19 vaccine response in immunosuppressed populations. Microbial diversity (alpha diversity) is decreased in immunosuppressed patients and might be associated with lower immunogenicity to vaccines.

It is known that patients with IBD have dysbiosis of their gut microbiome and those immunosuppressed may have a lower vaccine response. In this aim, the investigators will evaluate whether differences in microbial diversity predict immune response to the influenza and COVID-19 vaccine.

In this prospective study, immunosuppressed IBD patients will be vaccinated per standard of care and blood will be collected to measure the immune response. A fecal and saliva sample will be collected to characterize the gut microbiome. The investigators hypothesize that reduced richness / alpha-diversity in gut microbiota will correlate with those with a blunted vaccine response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Inflammatory Bowel Disease (IBD)

Participants with IBD who are receiving a flu or COVID-19 vaccine

Influenza vaccine

Intervention Type BIOLOGICAL

Observe effects of flu vaccine on microbiome

COVID-19 vaccine

Intervention Type BIOLOGICAL

Observe effects of COVID-19 vaccine on microbiome

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Influenza vaccine

Observe effects of flu vaccine on microbiome

Intervention Type BIOLOGICAL

COVID-19 vaccine

Observe effects of COVID-19 vaccine on microbiome

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic, and histopathologic criteria
* Currently one of the following groups:

1. Group A: Anti-TNF Therapy Group

* Maintenance monotherapy: infliximab (at least every 8 weeks), golimumab (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly)
* Combination Therapy: Anti-TNF Combination Therapy Group on anti-TNF therapy as described above along with either methotrexate, azathioprine, or 6MP
2. Group B: Non-TNG biologic

* Ustekinumab Therapy: on either ustekinumab monotherapy or combination therapy with methotrexate, azathioprine, or 6MP
* Vedolizumab Therapy: on either vedolizumab monotherapy or combination therapy with methotrexate, azathioprine, or 6MP
* Risankizumab Therapy: 360mg at least every 8 weeks
3. Group C: Janus Kinase Therapy

* Tofacitinib Therapy: at least 5mg PO BID
* Upadactinib Therapy: at least 15mg PO daily
* Patient has been on stable treatment for IBD for at least three months
* Must be able to provide research samples between 28-65 days post influenza or Covid-19 vaccination.